226 related articles for article (PubMed ID: 15310781)
1. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
[TBL] [Abstract][Full Text] [Related]
2. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
4. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
5. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
[TBL] [Abstract][Full Text] [Related]
8. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
9. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
10. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
11. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas.
Terterov S; Krieger MD; Bowen I; McComb JG
J Neurosurg Pediatr; 2010 Aug; 6(2):131-6. PubMed ID: 20672933
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
[TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
16. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
[TBL] [Abstract][Full Text] [Related]
17. [Current and future strategies in interdisciplinary treatment of medulloblastomas, supratentorial PNET (primitive neuroectodermal tumors) and intracranial germ cell tumors in childhood].
Kortmann RD; Kühl J; Timmermann B; Calaminus G; Dieckmann K; Wurm R; Sörensen N; Urban C; Göbel U; Bamberg M
Strahlenther Onkol; 2001 Sep; 177(9):447-61. PubMed ID: 11591018
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
[TBL] [Abstract][Full Text] [Related]
19. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
